Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan 430071, China.
King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, P. O. Box 80216, Saudi Arabia.
CNS Neurol Disord Drug Targets. 2021;20(8):687-693. doi: 10.2174/1871527319666201005171003.
Conventionally, cardiac biomarkers are recognized as an essential tool to investigate the presence or progression of various cardiovascular diseases. However, in recent years, data from several clinical trials have successfully sorted out the utility of cardiac biomarkers in diseases that are not primarily regarded as "cardiac diseases," especially neurological diseases. Results of freshly published trials have endorsed the use of cardiac biomarkers in various forms of stroke and dementia, including Alzheimer's disease. Alzheimer's disease is also one of the other CNS conditions where measuring cardiac biomarkers have been found to be useful. Cardiac biomarkers can be helpful in two ways. Firstly, to assess the secondary involvement of the heart during the progression of the primary disease. Secondly, they can be useful in the diagnosis and prognosis of the primary condition itself. In this short review, we have collected encouraging results from recent studies that show the importance of the most widely recognized cardiac biomarkers in two of the most prominent neurological diseases of the current world, i.e., stroke and dementia.
传统上，心脏生物标志物被认为是研究各种心血管疾病存在或进展的重要工具。然而，近年来，几项临床试验的数据成功梳理了心脏生物标志物在并非主要被视为“心脏病”的疾病中的效用，尤其是神经疾病。新发表的试验结果支持在各种形式的中风和痴呆症（包括阿尔茨海默病）中使用心脏生物标志物。阿尔茨海默病也是测量心脏生物标志物有用的另一种中枢神经系统疾病之一。心脏生物标志物可以通过两种方式提供帮助。首先，评估原发性疾病进展过程中心脏的继发性受累。其次，它们可用于原发性疾病本身的诊断和预后。在这篇简短的综述中，我们收集了最近的研究结果，这些结果表明，在当前世界上两种最突出的神经疾病（即中风和痴呆症）中，最广泛认可的心脏生物标志物的重要性。
